secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001104659-24-000353
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics raises $2M via private placement with insiders; now must file as domestic issuer
--------------------------------------------------------------------------------

- Closed private placement on Dec 29, 2023: 947,868 ADSs at $2.11/ADS for gross proceeds ~$2M from Chairman Dr. Ray Prudo and Director Samir R. Patel.
- Placement agent Paulson Investment Co. received 5% cash fee plus $60k expense allowance.
- Company to file resale registration statement on Form S-3 by March 31, 2024.
- Effective Jan 1, 2024, company no longer qualifies as foreign private issuer; must file domestic reports (Form 10-K), comply with US proxy rules and Section 16.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000110465924000353/0001104659-24-000353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000110465924000353/tm2334004d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer